Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb;17(2):71-72.
doi: 10.1038/s41584-020-00562-2.

Rheumatic disease and COVID-19: epidemiology and outcomes

Kimme L Hyrich  1 , Pedro M Machado  2
Affiliations
Review

Rheumatic disease and COVID-19: epidemiology and outcomes

Kimme L Hyrich et al. Nat Rev Rheumatol. 2021 Feb.

Abstract

Since the outset of the COVID-19 pandemic, numerous risk factors for severe disease have been identified. Whether patients with rheumatic diseases, especially those receiving DMARDs, are at an increased risk of SARS-CoV-2 infection or severe COVID-19 disease remains unclear, although epidemiological studies are providing some insight.

PubMed Disclaimer

Conflict of interest statement

K.L.H. declares that she has received consulting and speaker’s fees from Abbvie and grant income from BMS, Pfizer and UCB, all unrelated to this manuscript. P.M.M. has received consulting and speaker’s fees from Abbvie, BMS, Celgene, Eli Lilly, Janssen, MSD, Novartis, Orphazyme, Pfizer, Roche and UCB, all unrelated to this manuscript.

Figures

Fig. 1
Fig. 1. Factors associated with hospitalization for COVID-19 infection.
This graph visualizes data from 600 patients with rheumatic diseases recorded in the COVID-19 Global Rheumatology Alliance international physician registry, reported by Gianfrancesco et al.. Associations between the various factors and odds of hospitalization were estimated using multivariable-adjusted logistic regression and reported as odds ratios (ORs) with 95% confidence intervals. b/tsDMARD, biologic/targeted synthetic DMARD; CRI, chronic renal insufficiency; csDMARD, conventional synthetic DMARD; CVD, cardiovascular disease; ESRD, end-stage renal disease; GC, glucocorticoid.
See this image and copyright information in PMC

References

    1. World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard, https://covid19.who.int/ (2020).
    1. Williamson EJ, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584:430–436. doi: 10.1038/s41586-020-2521-4. - DOI - PMC - PubMed
    1. Simon D, et al. Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion. Nat. Commun. 2020;11:3774. doi: 10.1038/s41467-020-17703-6. - DOI - PMC - PubMed
    1. Gianfrancesco M, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann. Rheum. Dis. 2020;79:859–866. doi: 10.1136/annrheumdis-2020-217871. - DOI - PMC - PubMed
    1. Sepriano A, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann. Rheum. Dis. 2020;79:760–770. doi: 10.1136/annrheumdis-2019-216516. - DOI - PubMed

Publication types

MeSH terms

Substances